In our last review of CRISPR Therapeutics (CRSP) on March 23 we were bearish and recommended, "Avoid the long side of CRSP, as the charts and indicators point to the possibility of further steep losses."
More from Investing
The S&P 500 and DJIA are convenient benchmarks, but they can hurt your returns if you give them too much weight.
Here's what I found most positive about the market as the week closed out.
I like to identify a chart or two with a nice setup into the next week, and OB falls into that category.